The predominance of evidence indicates that the pulmonary disease associated with SARS COV2 virus is due to direct viral cytopathic effects and resultant innate immune system responses that are then later amplified by cognate immure responses, particularly via anti-SARS CoV2 antibody production and resultant "disease enhancement" mediated by these antibodies.
The pathogenesis of coronavirus infections and pulmonary lesions has been an area of intense study since the first two coronavirus outbreaks - MERS and SARS. SARS COV2 shares substantial genetic sequence homology with SARS (79.6% homology) and other coronaviruses. Thus, lessons from these two diseases have direct implications for understanding of SARS Cov2 infections (ie, COVID). The strongest evidence to date explaining the pulmonary pathology associated with coronaviruses comes from Liu et al JCI Insight 2019 (fulll citation given below) and is summarized by the following:
1) the SARS COV2 virus binds to ACE2 receptors in pulmonary epithelia and the initial viral cytopathologic effects occur in pulmonary epithelium and endothelium (which also richly expresses ACE2- the SARS COV2 viral receptor)
2) initial pulmonary inflammation is mediated by an innate immune response to the virus which can be intense and obliterate small airways and alveoli.
3)the outcome- either recovery or severe pulmonary deterioration and cytokine storm result from the appearance of anti-SARS Cov2 antibodies in the serum of patients between 7 and 14 days of infection. If these antibodies are neutralizing (ie, the bind to the RBD (receptor binding domain) component of the SARS COV2 spike protein, the patient will improve. However, if the antibodies are not neutralizing (ie, the bind to other areas of the spike protein or other viral surface proteins, they may mediate a phenomenon termed "disease enhancement" where the antibodies bind to viral particles, opsonizing them, and then bind to monocytes and macro****es in the lungs that have been previously activated and trafficked to the lung. Binding of these antibodies binds to the high affinity Fc receptor (CD64) on monocytes and macro****es, resulting in intense activation and cytokine production (IL-1, IL-6, TNF, IL-10, MCP1 amongst others).
Thus the pneumonitis of COVID is an intense combination of viral cytopathic effects and inflammation. These same mechanisms occur with SARS, MERS, and severe influenza, and RSV. Disease enhancement is why there are no successful RSV vaccines to date. Disease enhancement will be the major risk associated with vaccine development for COVID. Currently, vaccine leaders in big pharma are actively designing vaccines so that neutralizing antibodies are the consistent and primary result rather than non-neutralizing antibodies.
The reason that RSV vaccines failed in the late 1960s is that they produced primarily disease enhancing antibodies rather than neutralizing antibodies.
one explanation for why diabetes is associated with increased risks is that diabetes markedly increases expression of ACE2, the SARS COV2 receptor.....
Those interested in the scientific literature supporting these observations should start with the reference list in
Anti-spike IgG causes severe acute lung injury by skewing macro****e responses during acute SARS-CoV infection.Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z.
JCI Insight. 2019 Feb 21;4(4). pii: 123158. doi: 10.1172/jci.insight.123158. eCollection 2019 Feb 21.
PMID: 30830861
No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. See full
Medical Disclaimer.